Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
This process entails comprehensive molecular simulations of the target protein, individually and in complex with essential partner proteins, along with ensemble virtual screening that focuses on conformational mobility in both its free and complex states. Potential binding pockets are considered at the protein-protein interaction interface and in remote allosteric locations to address every conceivable mechanism of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y6H5
UPID:
SNCAP_HUMAN
Alternative names:
Alpha-synuclein-interacting protein
Alternative UPACC:
Q9Y6H5; D3DSZ1; Q05BS1; Q1PSC2; Q49AC6; Q504U9; Q6L984; Q6L985; Q6L986; Q9HC59
Background:
Synphilin-1, known as Alpha-synuclein-interacting protein, plays a crucial role in neurodegenerative processes. It inhibits the ubiquitin ligase activity of SIAH1, preventing proteasomal degradation of target proteins. This action increases cellular levels of SIAH and modulates SNCA monoubiquitination, highlighting its significant regulatory functions in cellular pathways.
Therapeutic significance:
Given its involvement in Parkinson disease, characterized by the loss of dopaminergic neurons and presence of Lewy bodies, Synphilin-1 presents a promising target for therapeutic intervention. Understanding its role could lead to novel strategies for managing this complex neurodegenerative disorder.